Total Payments
$86,283
2024 Payments
$12,166
Companies
15
Transactions
107
Medicare Patients
741
Medicare Billing
$99,867
Payment Breakdown by Category
Consulting$60,233 (69.8%)
Other$13,312 (15.4%)
Research$7,000 (8.1%)
Travel$3,025 (3.5%)
Food & Beverage$2,645 (3.1%)
Education$68.17 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $60,233 | 30 | 69.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,312 | 14 | 15.4% |
| Unspecified | $7,000 | 7 | 8.1% |
| Travel and Lodging | $3,025 | 11 | 3.5% |
| Food and Beverage | $2,645 | 43 | 3.1% |
| Education | $68.17 | 2 | 0.1% |
Payments by Type
General
$79,284
100 transactions
Research
$7,000
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $30,821 | 32 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $18,449 | 20 | $0 (2024) |
| PFIZER INC. | $13,231 | 11 | $0 (2024) |
| F. Hoffmann-La Roche AG | $7,412 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,911 | 10 | $0 (2024) |
| Stemline Therapeutics Inc. | $4,080 | 2 | $0 (2022) |
| Eli Lilly and Company | $3,196 | 4 | $0 (2021) |
| Daiichi Sankyo Inc. | $1,801 | 4 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,370 | 1 | $0 (2022) |
| Gilead Sciences, Inc. | $761.40 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,166 | 9 | PFIZER INC. ($5,423) |
| 2023 | $14,528 | 17 | Seagen Inc. ($11,660) |
| 2022 | $12,693 | 16 | Stemline Therapeutics Inc. ($4,080) |
| 2021 | $15,141 | 14 | AstraZeneca Pharmaceuticals LP ($9,807) |
| 2020 | $18,299 | 20 | Seagen Inc. ($14,389) |
| 2019 | $4,669 | 13 | Eli Lilly and Company ($1,441) |
| 2018 | $4,235 | 7 | F. Hoffmann-La Roche AG ($2,442) |
| 2017 | $4,553 | 11 | PFIZER INC. ($3,808) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $2,159.82 | Research |
| Study: T DM1 high risk EBC pts with residual inv disease • Category: BioOncology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 06/28/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,217.50 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $45.41 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $97.93 | General |
| 05/19/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | PFIZER INC. | IBRANCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,205.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $115.40 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.20 | General |
| 12/05/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| 12/05/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $101.68 | General |
| 11/21/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| Category: ONC | ||||||
| 10/27/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $112.60 | General |
| Category: ONC | ||||||
| 09/19/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $86.59 | General |
| Category: Oncology | ||||||
| 07/10/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Oncology | ||||||
| 05/26/2023 | Seagen Inc. | TUKYSA (Drug) | Consulting Fee | Cash or cash equivalent | $10,150.00 | General |
| Category: Oncology | ||||||
| 05/12/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $331.41 | General |
| Category: Oncology | ||||||
| 05/12/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $80.00 | General |
| Category: Oncology | ||||||
| 05/12/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $59.05 | General |
| Category: Oncology | ||||||
| 05/12/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Oncology | ||||||
| 05/12/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $21.52 | General |
| 05/11/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $672.80 | General |
| Category: Oncology | ||||||
| 05/11/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $320.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $3,196 | 4 |
| T DM1 high risk EBC pts with residual inv disease | F. Hoffmann-La Roche AG | $2,160 | 1 |
| A Randomized, Multicenter, Open-Label Phase III Study to Evaluate Efficacy and Safety of Trastuzumab Emtansine vs Trastuzumab as Adjuvant Therapy for Patients with HER2 Primary Breast Cancer with Residual Tumor Present Pathologically in Breast or Axillary Lymph Nodes Following Preoperative Therapy | F. Hoffmann-La Roche AG | $1,071 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY | F. Hoffmann-La Roche AG | $572.31 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 176 | 283 | $108,294 | $23,359 |
| 2022 | 4 | 163 | 263 | $106,943 | $23,177 |
| 2021 | 4 | 185 | 322 | $131,636 | $29,796 |
| 2020 | 6 | 217 | 371 | $100,233 | $23,536 |
Total Patients
741
Total Services
1,239
Medicare Billing
$99,867
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 32 | 103 | $49,234 | $11,019 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 123 | $39,975 | $8,070 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $10,285 | $2,505 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 37 | 40 | $8,800 | $1,765 | 20.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 107 | $51,360 | $11,864 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 109 | $35,207 | $7,393 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $15,756 | $2,939 | 18.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 21 | $4,620 | $979.88 | 21.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 150 | $72,450 | $16,922 | 23.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 92 | 122 | $39,650 | $8,606 | 21.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $13,376 | $3,212 | 24.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 25 | 28 | $6,160 | $1,056 | 17.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 28 | 122 | $43,432 | $10,883 | 25.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 110 | 140 | $22,960 | $4,643 | 20.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $15,660 | $3,567 | 22.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 40 | $10,080 | $2,389 | 23.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 23 | $5,313 | $1,372 | 25.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 14 | 17 | $2,788 | $682.42 | 24.5% |
About Dr. Alison Conlin, MD
Dr. Alison Conlin, MD is a Medical Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1841460193.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alison Conlin, MD has received a total of $86,283 in payments from pharmaceutical and medical device companies, with $12,166 received in 2024. These payments were reported across 107 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($60,233).
As a Medicare-enrolled provider, Conlin has provided services to 741 Medicare beneficiaries, totaling 1,239 services with total Medicare billing of $99,867. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Portland, OR
- Active Since 03/03/2008
- Last Updated 02/19/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1841460193
Products in Payments
- TUKYSA (Drug) $22,385
- IBRANCE (Drug) $9,269
- Kadcyla (Biological) $7,358
- ENHERTU (Biological) $4,359
- LYNPARZA (Drug) $3,630
- PIQRAY (Drug) $2,787
- Enhertu (Drug) $1,665
- Truqap (Drug) $1,665
- KISQALI (Drug) $1,478
- Vitrakvi (Drug) $1,370
- Trodelvy (Drug) $632.60
- Perjeta (Biological) $94.78
- VERZENIO (Drug) $82.93
- Herceptin (Biological) $54.13
- ENHERTU (Drug) $53.29
- Neulasta (Biological) $31.13
- PROSIGNA ASSAY (Device) $23.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Portland
Matthew Taylor, Md, MD
Medical Oncology — Payments: $325,133
Medical Oncology $325,133
David Page, M.d, M.D
Medical Oncology — Payments: $236,791
Medical Oncology $236,791
Tomasz Beer, Md, MD
Medical Oncology — Payments: $179,452
Medical Oncology $179,452
Brendan Curti, Md, MD
Medical Oncology — Payments: $66,023
Medical Oncology $66,023
Christopher Ryan, Md, MD
Medical Oncology — Payments: $52,261
Medical Oncology $52,261
Dr. Jason Taylor, Md, Phd, MD, PHD
Medical Oncology — Payments: $42,506
Medical Oncology $42,506